Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
暂无分享,去创建一个
Yifan Sun | Yujing Li | Cecil Han | Xinna Zhang | Xiongbin Lu | Gang Zhao | J. Wan | X. He | Hanchen Xu | G. Ji | Sheng Liu | Yifan Sun | Yunhua Liu | Lifei Wang | Yuntian Zhang | Cheng Huang | Kevin Van der Jeught | H. Choi | Jiangsheng Xu | Lu Zhang | Guang Ji | Yuanzhang Fang | Haniyeh Eyvani | Michael Frieden | Xiaoming He | Gang Zhao
[1] Christopher M. Thompson,et al. Isolation of Intact, Whole Mouse Mammary Glands for Analysis of Extracellular Matrix Expression and Gland Morphology. , 2017, Journal of visualized experiments : JoVE.
[2] J. Pober,et al. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells , 2017, Nature Communications.
[3] N. Williams,et al. CO2 Capture from Ambient Air by Crystallization with a Guanidine Sorbent. , 2017, Angewandte Chemie.
[4] Jing Wang,et al. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer , 2016, Modern Pathology.
[5] John J Rossi,et al. RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? , 2016, Annual review of pharmacology and toxicology.
[6] Xiongbin Lu,et al. A Near‐Infrared Laser‐Activated “Nanobomb” for Breaking the Barriers to MicroRNA Delivery , 2016, Advanced materials.
[7] Xiongbin Lu,et al. A Near-Infrared Laser-Activated "Nanobomb" for Breaking the Barriers to MicroRNA Delivery. , 2016, Advanced materials.
[8] Xiongbin Lu,et al. Nanoparticle systems reduce systemic toxicity in cancer treatment. , 2016, Nanomedicine.
[9] Xiongbin Lu,et al. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. , 2015, Biomaterials.
[10] Mark E. Davis,et al. Clinical experiences with systemically administered siRNA-based therapeutics in cancer , 2015, Nature Reviews Drug Discovery.
[11] Steven J. M. Jones,et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.
[12] J. Lieberman,et al. Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.
[13] T. Paull. Mechanisms of ATM Activation. , 2015, Annual review of biochemistry.
[14] R. Gregory,et al. MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.
[15] Xiongbin Lu,et al. Abstract A36: TP53 loss creates therapeutic vulnerability in colorectal cancer , 2017 .
[16] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[17] D. Bulavin,et al. Wip1 phosphatase in breast cancer , 2014, Oncogene.
[18] A. Sood,et al. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. , 2014, Cell reports.
[19] Daniel G. Anderson,et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. , 2014, Nature nanotechnology.
[20] Neysa Nevins,et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. , 2014, Nature chemical biology.
[21] Cecil Han,et al. Noncoding RNAs in DNA repair and genome integrity. , 2014, Antioxidants & redox signaling.
[22] R. Losick,et al. Synthesis and Activity of Biomimetic Biofilm Disruptors , 2013, Journal of the American Chemical Society.
[23] F. Fuller-Pace,et al. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell cycle arrest after DNA damage , 2012, Oncogene.
[24] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[25] R. Losick,et al. Synthesis and Activity of Biomimetic Bio fi lm Disruptors , 2013 .
[26] D. Zardavas,et al. Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer , 2012, Current opinion in oncology.
[27] Myriam Gorospe,et al. MS2-TRAP (MS2-tagged RNA affinity purification): tagging RNA to identify associated miRNAs. , 2012, Methods.
[28] Bruce Stillman,et al. DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. , 2012, Cancer discovery.
[29] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[30] H. Stern. Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges , 2012, Science Translational Medicine.
[31] Munish Kumar,et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis , 2011, Proceedings of the National Academy of Sciences.
[32] M. Jackson,et al. TGF-β signaling engages an ATM-CHK2-p53–independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells , 2011, Proceedings of the National Academy of Sciences.
[33] Hua Guo,et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.
[34] Zhang,et al. Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling Pathway , 2010 .
[35] M. Smalley. Isolation, culture and analysis of mouse mammary epithelial cells. , 2010, Methods in molecular biology.
[36] C. Perou,et al. Mammary development meets cancer genomics , 2009, Nature Medicine.
[37] S. Fox,et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.
[38] Hiroshi I. Suzuki,et al. Modulation of microRNA processing by p53 , 2009, Nature.
[39] N. Sharpless,et al. p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age. , 2009, Developmental cell.
[40] J. Baselga,et al. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.
[41] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[42] Lyndsay Harris,et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Yolanda F. Darlington,et al. The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways , 2008, Cancer and Metastasis Reviews.
[44] K. Ghoshal,et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.
[45] B. A. Ballif,et al. ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.
[46] E. Appella,et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis , 2007, Oncogene.
[47] A. Alavi,et al. Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.
[48] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[49] Romayne A. Thompson,et al. Age-related lobular involution and risk of breast cancer. , 2006, Journal of the National Cancer Institute.
[50] L. Donehower,et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice , 2006, Molecular carcinogenesis.
[51] R. Shiekhattar,et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.
[52] T. Ørntoft,et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.
[53] K. Hunt,et al. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. , 2004, Surgery.
[54] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[55] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[56] K. Gelmon,et al. Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction , 2004, Clinical Cancer Research.
[57] L. Donehower,et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK–mediated activation of the p16Ink4a-p19Arf pathway , 2004, Nature Genetics.
[58] K. Ang,et al. Sensitization of breast cancer cells to radiation by trastuzumab. , 2003, Molecular cancer therapeutics.
[59] Y. Shiloh. ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.
[60] Jeffrey R. Marks,et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 , 2002, Nature Genetics.
[61] Albert J. Fornace,et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.
[62] Lawrence A. Donehower,et al. Mice Deficient for the Wild-Type p53-Induced Phosphatase Gene (Wip1) Exhibit Defects in Reproductive Organs, Immune Function, and Cell Cycle Control , 2002, Molecular and Cellular Biology.
[63] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[65] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.